Conservative treatment of invasive bladder cancer

Current Oncology

Volumn 16, Issue 4, 2009, Pages 36-47

  Rene, N J ^a   Cury, F B ^a   Souhami, Luis ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Bladder cancer; Bladder preservation; Chemotherapy; Conservative treatment; Radiation therapy; Radiochemotherapy; Trimodality therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; VINBLASTINE;

BLADDER CANCER; BLADDER TUMOR; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CYSTECTOMY; HUMAN; PATIENT SELECTION; REVIEW; SURVIVAL RATE; TRANSURETHRAL RESECTION;

EID: 70350590937     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-675 (Pubitemid 32120143)
3. Chung PW, Bristow RG, Milosevic MF, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007;25:303-309 (Pubitemid 47031001)
4. Coppin CM, Gospodarowicz MK, James K, et al. on behalf of the National Cancer Institute of Canada Clinical Trials Group. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. J Clin Oncol 1996;14:2901-2907
5. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150-2157 (Pubitemid 23332251)
6. Kent E, Sandler H, Montie J, et al. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol 2004;22:2540-2545 (Pubitemid 41103741)
7. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002;20:3061-3071 (Pubitemid 34791095)
8. Sangar VK, McBain CA, Lyons J, et al. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 2005;61:420-425 (Pubitemid 40164436)
9. Shipley WU, Kaufman DS, Zehr E, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002;60:62-68 (Pubitemid 34722947)
10. Cruciani G, Dazzi C, Montanari F, et al. Conservative treatment for T2-T4 bladder cancer with primary chemotherapy and radiotherapy: a pilot study. Tumori 1993;79:53-57 (Pubitemid 23184174)
11. Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase ii study. Br J Urol 1997;80:44-49 (Pubitemid 28316708)
12. Schmitt T, Armand C, Mille D, Favrel-Tchakamian V, Gilloz A. Concurrent chemotherapy and hyperfractionated radiotherapy for non-operable carcinoma of the bladder [French]. Cancer Radiother 1998;2(suppl 1):82s-4s.
13. Arias F, Dominguez MA, Martinez E, et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 2000;47:373-378 (Pubitemid 30236378)
14. Cobo M, Delgado R, Gil S, et al. Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer. Clin Transl Oncol 2006;8:903-911
15. George L, Bladou F, Bardou VJ, et al. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy. Urology 2004;64:488-493 (Pubitemid 39200744)
16. Ibrahim SM, Abd El-Hafeez ZM, Mohamed EM, Elsharawy IA, Kamal KM. Transurethral resection of bladder tumor (TUR-BT) then concomitant radiation and cisplatin followed by adjuvant gemcitabine and cisplatin in muscle invasive transitional cell carcinoma (TCC) of the urinary bladder. J Egypt Natl Canc Inst 2007;19:77-86.
17. Danesi DT, Arcangeli G, Cruciani E, et al. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results. Cancer 2004;101:2540-2548 (Pubitemid 39532283)
18. Eapen L, Stewart D, Collins J, Peterson R. Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer. J Urol 2004;172:1276-1280 (Pubitemid 39249697)
19. Hata M, Miyanaga N, Tokuuye K, et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys 2006;64:1371-1379
20. Hoshi S, Shintaku I, Suzuki K, et al. Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years. Tohoku J Exp Med 2000;192:249-258 (Pubitemid 32367724)
21. Ikushima H, Iwamoto S, Osaki K, et al. Effective bladder preservation strategy with low-dose radiation therapy and concurrent intraarterial chemotherapy for muscle-invasive bladder cancer. Radiat Med 2008;26:156-163 (Pubitemid 351652567)
22. Miyanaga N, Akaza H, Hinotsu S, et al. Background variables for the patients with invasive bladder cancer suitable for bladder- preserving therapy. Jpn J Clin Oncol 2007;37:852-857 (Pubitemid 350259004)
23. Miyanaga N, Akaza H, Okumura T, et al. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. Int J Urol 2000;7:41-48 (Pubitemid 30167046)
24. Mokarim A, Uetani M, Hayashi N, et al. Combined intraarterial chemotherapy and radiotherapy in the treatment of bladder carcinoma. Cancer 1997;80:1776-1785 (Pubitemid 27475936)
25. Mori K, Nomata K, Noguchi M, Eguchi J, Hayashi N, Kanetake H. Long-term follow up of patients with invasive bladder carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy. Int J Urol 2007;14:591-594 (Pubitemid 47084101)
26. Sumiyoshi Y, Uyama T, Kagawa S. Intra-arterial Adriamycin chemotherapy in combination with radiotherapy for advanced bladder cancer. Cancer Chemother Pharmacol 1992;30(suppl):S5-9.
27. Tsujii H, Akaza H, Ohtani M, et al. Preliminary results of bladder-preserving therapy with definitive radiotherapy and intraarterial infusion of chemotherapy. Strahlenther Onkol 1994;170:531-537 (Pubitemid 24290722)
28. Cookson MS. The surgical management of muscle invasive bladder cancer: a contemporary review. Semin Radiat Oncol 2005;15:10-18. (Pubitemid 40127274)
29. Huang GJ, Stein JP. Open radical cystectomy with lymphadenectomy remains the treatment of choice for invasive bladder cancer. Curr Opin Urol 2007;17:369-375 (Pubitemid 47344626)
30. Hautmann RE, Abol-Enein H, Hafez K, et al. Urinary diversion. Urology 2007;69:17-49.
31. Halperin EC, Perez CA, Brady L. Perez and Brady's Principles and Practice of Radiation Oncology. 5th ed. Philadelphia: Lippincott Williams and Wilkins; 2008.
32. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986;7:299-310. (Pubitemid 17232169)
33. Goffinet DR, Schneider MJ, Glatstein EJ, et al. Bladder cancer: results of radiation therapy in 384 patients. Radiology 1975;117:149-153
34. Gospodarowicz MK, Hawkins NV, Rawlings GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. J Urol 1989;142:1448-1454
35. Jenkins BJ, Caulfield MJ, Fowler CG, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988; 62:343-346
36. Mameghan H, Fisher R, Mameghan J, Brook S. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995;31:247-254
37. Shipley WU, Rose MA, Perrone TL, Mannix CM, Heney NM, Prout GR Jr. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol 1985;134:679-683
38. Wallace DM, Bloom HJ. The management of deeply infiltrating (T3) bladder carcinoma: controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report). Br J Urol 1976;48:587-594
39. Mameghan H, Fisher RJ, Watt WH, et al. The management of invasive transitional cell carcinoma of the bladder. Results of definitive and preoperative radiation therapy in 390 patients treated at the Prince of Wales Hospital, Sydney, Australia. Cancer 1992;69:2771-2778
40. Bloom HJ, Hendry WF, Wallace DM, Skeet RG. Treatment of T3 bladder cancer: controlled trial of pre-operative radiotherapy and radical cystectomy versus radical radiotherapy. Br J Urol 1982;54:136-151
41. Miller LS. Bladder cancer: superiority of preoperative irradiation and cystectomy in clinical stages B2 and C. Cancer 1977;39:973-980 (Pubitemid 8060291)
42. Sell A, Jakobsen A, Nerstrøm B, Sørensen BL, Steven K, Barlebo H on behalf of the Danish Vesical Cancer Group. Treatment of advanced bladder cancer category T2 T3 and T4a. A randomized multicenter study of preoperative irradiation and cystectomy versus radical irradiation and early salvage cystectomy for residual tumor. DAVECA protocol 8201. Scand J Urol Nephrol Suppl 1991;138:193-201.
43. Hayter CR, Paszat LF, Groome PA, Schulze K, Mackillop WJ. The management and outcome of bladder carcinoma in Ontario, 1982-1994. Cancer 2000;89:142-151
44. Scrimger RA, Murtha AD, Parliament MB, et al. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors. Int J Radiat Oncol Biol Phys 2001;51:23-30. (Pubitemid 32758857)
45. James N, Hussain SA. Management of muscle invasive bladder cancer - British approaches to organ conservation. Semin Radiat Oncol 2005;15:19-27. (Pubitemid 40127275)
46. Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 2003;97:2115-2119 (Pubitemid 36397252)
47. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15:1022-1029 (Pubitemid 27106286)
48. Weiss C, Engehausen DG, Krause FS, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68:1072-1080 (Pubitemid 47048579)
49. Housset M, Dufour B, Maulard-Durdux C, Chretien Y, Mejean A. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractionated split course radiation therapy (BSCRT) for invasive bladder cancer [abstract 1139]. Proc Am Soc Clin Oncol 1997;15:. [Available online at: www.asco.org/ASCOv2/ Meetings/Abstracts? &vmview=abst-detail-view&confID=30 &abstractID=11564; cited May 6, 2009]
50. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25:783-790 (Pubitemid 23123381)
51. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 1996;14:119-126 (Pubitemid 26020004)
52. Shipley WU, Winter KA, Kaufman DS, et al. Phase iii trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576-3583
53. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471-476
54. Hagan MP, Winter KA, Kaufman DS, et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003;57:665-672
55. Kaufman D, Winter K, Shipley W, et al. Muscle-invading bladder cancer, RTOG protocol 99-06: initial report of a phase I/II trial of selective bladder-conservation employing TURBT, accelerated irradiation sensitized with cisplatin and paclitaxel followed by adjuvant cisplatin and gemcitabine chemotherapy [abstract 4506]. Proc Am Soc Clin Oncol 2005;23:. [Available online at: www. asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=34&abstractID=30650; cited May 6, 2009]
56. Perdona S, Autorino R, Damiano R, et al. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer 2008;112:75-83.
57. Shipley WU, Zietman AL, Kaufman DS, Coen JJ, Sandler HM. Selective bladder preservation by trimodality therapy for patients with muscularis propria - invasive bladder cancer and who are cystectomy candidates - the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005;15:36-41.
58. Milosevic M, Gospodarowicz M, Zietman A, et al. Radiotherapy for bladder cancer. Urology 2007;69:80-92.
59. Weiss C, Wittlinger M, Engehausen DG, et al. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy. Int J Radiat Oncol Biol Phys 2008;70:1502-1506
60. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001;58:380-385 (Pubitemid 32816355)
61. Cooke PW, Dunn JA, Latief T, Bathers S, James ND, Wallace DM. Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer. Eur Urol 2000;38:279-286 (Pubitemid 30665954)
62. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-477 (Pubitemid 43259554)
63. Bochner BH, Figueroa AJ, Skinner EC, et al. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol 1998;160:29-33.
64. Mannel RS, Manetta A, Buller RE, Braly PS, Walker JL, Archer JS. Use of ileocecal continent urinary reservoir in patients with previous pelvic irradiation. Gynecol Oncol 1995;59:376-378
65. Rodel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006;24:5536-5544 (Pubitemid 46631334)
66. Wright JL, Porter MP. Quality-of-life assessment in patients with bladder cancer. Nat Clin Pract Urol 2007;4:147-154 (Pubitemid 46416279)
67. Mottet N, Castagnola C, Rischmann P, et al. Quality of life after cystectomy: French national survey conducted by the French Association of Urology (AFU), the French Federation of Stoma Patients (FSF) and the French Association of Enterostomy Patients (AFET) in patients with ileal conduit urinary diversion or orthotopic neobladder [French]. Prog Urol 2008;18:292-298
68. Hart S, Skinner EC, Meyerowitz BE, Boyd S, Lieskovsky G, Skinner DG. Quality of life after radical cystectomy for bladder cancer in patients with an ileal conduit, cutaneous or urethral kock pouch. J Urol 1999;162:77-81. (Pubitemid 29420884)
69. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003;170:1772-1776 (Pubitemid 37254925)
70. Kikuchi E, Horiguchi Y, Nakashima J, et al. Assessment of long-term quality of life using the FACT-BL questionnaire in patients with an ileal conduit, continent reservoir, or orthotopic neobladder. Jpn J Clin Oncol 2006;36:712-716
71. Schoenberg MP, Walsh PC, Breazeale DR, Marshall FF, Mostwin JL, Brendler CB. Local recurrence and survival following nerve sparing radical cystoprostatectomy for bladder cancer: 10-year followup. J Urol 1996;155:490-494
72. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and HER-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005;62:309-317
73. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120-1125 (Pubitemid 24161872)